Description of Business

9 Months Ended

Sep. 30, 2015

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]

Note 1 – Description of Business

Organization and Description of Business

Immune Pharmaceuticals Inc., together with its subsidiaries (“Immune”, “we”, “us”, “our” or the “Company”), is a clinical stage biopharmaceutical company specializing in the development and commercialization of novel targeted therapeutics in the fields of immuno-inflammation and immuno-oncology. The Company favors a precision medicine approach to treatment, with patient selection and companion diagnostics. The Company’s product candidates pipeline includes: bertilimumab, a clinical-stage first-in-class fully human antibody, targeting eotaxin-1, a key regulator of immuno-inflammation based on the use of biomedicine in clinical development for ulcerative colitis and bullous pemphigoid, topical nano-formulated cyclosporin-A for the treatment of atopic dermatitis (eczema) and psoriasis and NanomAbs^® a technology platform that allows the targeted delivery of cancer drugs. The Company continues to review opportunities relating to the Company’s non-core assets with a focus on AmiKet^TM, a late stage clinical candidate for the treatment of neuropathic pain.

On November 9, 2015, the Company announced that U.S. Food and Drug Administration (“FDA”) has cleared an Investigational New Drug (“IND”) application in the U.S. to allow the Company’s recruiting for its Phase II clinical trials with bertilimumab, for the treatment of bullous pemphigoid (“BP”), a rare autoimmune skin disease known to have increased eotaxin-1 levels in serum and blister fluids.